Abstract:ObjectiveThe aim of this article is to assess the risk and potential mechanisms of cardiovascular adverse events in patients treated with nilotinib or imatinib by conducting a systematic review, meta-analysis and integrative bioinformatics analysis.Materials and methodsThree databases were systematically searched for studies published from inception to May 29, 2022. Differential expression analysis and weighted gene coexpression network analysis (WGCNA) were performed to search for modules of genes most associated with cardiotoxicity. Protein-protein interaction (PPI) network analysis was then performed to identify hub genes for the cardiotoxicity of nilotinib. Molecular docking was used to analyze the effects of rosuvastatin and aspirin on these targets.ResultsPatients treated with nilotinib as first-line treatment were associated with a higher risk of CAE (OR = 3.43 [95% CI 2.77–4.25]), CAD (OR = 5.30 [95% CI 3.85–7.29]), ACS (OR 2.7 [95% CI 1.60–4.54]), CVA (OR 5.76 [95% CI 2.84–11.28]), PAOD (OR 5.57 [95% CI 3.26–9.50]) and arrhythmia (OR 2.34 [1.17,4.67]) than those treated with imatinib, while no significant difference was found in the risk of HF (OR 1.40 [95% CI 0.42–4.69]) between the two groups. Patients who were treated with more than 600 mg daily dosage of nilotinib or followed up for more than 5 years had a higher risk of ACS and CVA. IL6, CXCL8, CCL2, SOD2, NFKBIA, and BIRC3 were identified as the top 6 hub genes in the magenta module (human cardiomyocyte samples) and were mainly enriched in the NOD-like receptor signaling pathway, IL-17 signaling pathway, TNF signaling pathway, lipid and atherosclerosis signaling pathway. TYROBP and CSF1R were identified as hub genes in the turquoise module (liver samples from Mus musculus). GSEA results showed that type II diabetes mellitus, B-cell receptor, apoptosis, insulin, natural killer cell mediated cytotoxicity,mTOR, chemokine, and T-cell receptor signaling pathways were related to the higher risk of atherosclerosis caused by nilotinib. Rosuvastatin can effectively bind to most of the hub targets and proteins enriched in the inflammatory pathways above.ConclusionCML patients who start with nilotinib have a higher risk of CAE than those with imatinib. Atherosclerosis caused by the inflammatory response and glycolipid metabolism disorder is the key mechanism of nilotinib cardiotoxicity. Rosuvastatin may be an effective treatment for the cardiotoxicity of nilotinib.

Nilotinib-induced Hypothyroidism in a Patient with Chronic Myeloid Leukemia

Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia

Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia

Acute ischemic intestinal necrosis as a rare side effect of nilotinib

[A Case of Chronic Myelogenous Leukemia That Developed Fibrous Pericarditis Owing to Nilotinib Use].

[Hepatic Adverse Events Associated with Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia].

Nilotinib-Associated Atherosclerosis Presenting as Multifocal Intracranial Stenosis and Acute Stroke

Progress in studies on hypothyroidism induced by sunitinib

Nilotinib-induced liver injury: A case report

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS)

Cardiovascular Adverse Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib or Imatinib: A Systematic Review, Meta-Analysis and Integrative Bioinformatics Analysis

Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis

Nilotinib Treatment for Imatinib Resistant or Intolerant Chronic Myelogenous Leukemia

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

Effect of Nilotinib on Proliferation and Function of Cd8+T Lymphocytes and the Role of T Cell Receptor Signaling

Cardiovascular Toxicity Associated With Tyrosine Kinase Inhibitor Therapy In Chronic Myeloid Leukemia

Assessment of Chronic Renal Injury in Patients with Chronic Myeloid Leukemia in the Chronic Phase Receiving Tyrosine Kinase Inhibitors

Eltrombopag for tyrosine kinase inhibitors-associated thrombocytopenia in chronic myeloid leukemia

Efficacy of nilotinib for chronic myeloid leukemia in chronic phase and accelerated phase

Data Mining and Analysis for Nilotinib Adverse Event Signals Based on the Food and Drug Administration Adverse Event Reporting System Database